Usinger
Laurie Usinger, Lafayette, CA US
Patent application number | Description | Published |
---|---|---|
20130045471 | TRAINING SYSTEM FOR INVESTIGATIONS OF BIOENGINEERED PROTEINS - Education and training in the procedures and materials for cell growth and protein expression are provided by an integrated system of modules, each fully equipped with reagents, for the entire span of procedures beginning with cell plating and inoculation and extending through protein expression, growth, purification, and assay, plus an instruction manual that sets forth all of the procedures, and in certain cases an assessment module. The system is supplied with bacterial cells already transformed for expression of proteins that are selected for their known expression procedures and properties, and is adaptable to any known protein. | 02-21-2013 |
William Usinger, Lafayette, CA US
Patent application number | Description | Published |
---|---|---|
20120020971 | ANTIBODIES USEFUL IN PASSIVE INFLUENZA IMMUNIZATION - Monoclonal antibodies and fragments thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza. | 01-26-2012 |
20120020980 | HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN CYTOMEGALOVIRUS (CMV) GB PROTEIN - Antibodies to human Cytomegalovirus (CMV) gB protein have been isolated from human B cells. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy. | 01-26-2012 |
20140322210 | ANTIBODIES USEFUL IN PASSIVE INFLUENZA IMMUNIZATION - Specific monoclonal antibodies and fragments including bispecific antibodies thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza. | 10-30-2014 |
William R. Usinger, Lafayette, CA US
Patent application number | Description | Published |
---|---|---|
20090017043 | Connective tissues growth factor antibodies - The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney. | 01-15-2009 |
20090325302 | Diagnostic marker for diabetic vascular complications - The present invention relates to the discovery that CTGF is a diagnostic marker indicative of increased risk for development and progression of vascular disease. | 12-31-2009 |
20100291098 | Diabetic nephropathy therapies - The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided. | 11-18-2010 |
20110091468 | Connective tissue growth factor antibodies - The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney. | 04-21-2011 |
20140073047 | Connective Tissue Growth Factor Antibodies - The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney. | 03-13-2014 |